Serious injuries and deaths have occurred due to the failure of a Tyco surgical stapler Duet TRS in the thoracic cavity


… Covidien (formerly United States Surgical, a division of Tyco Healthcare Group, L. P.) is conducting a FSCA of all production lots for the Duet TRS™ Universal Straight and Articulating Single Use Loading Units (SULU) with respect to the use of this product family in the thoracic cavity.

Serious injuries and deaths have occurred due to the failure mode associated with this FSCA. Covidien has received reports of 3 deaths and 13 serious injuries following the application of Duet TRS™ Loading Units in the thoracic cavity. We have concluded that Duet TRS™ has the potential to injure adjacent anatomical structures within the thorax which may result in life threatening post-operative complications.

Users of Duet TRS™ Loading Units should not use the device in thoracic surgery in both adult and paediatric populations.

Users of Duet TRS™ may continue to use Duet TRS™ in other applications.

Covidien will be revising the Instructions for Use for the Duet TRS™ to contraindicate the Duet TRS™ for use in thoracic procedures in adult and paediatric populations. In the interests of patient safety we are initiating this FSCA in advance of that change.

This FSCA only applies to the Duet TRS™ loading units and only for the use of this product in the thoracic cavity. Other Endo GIA™ families of SULUs are not affected.

The affected product codes and descriptions are as follows:

DUET4535
Duet TRS™ 45 3.5MM STRAIGHT SULU
DUET4535A
Duet TRS™ 45 3.5MM ARTICULATING SULU
DUET4548
Duet TRS™ 45 4.8MM STRAIGHT SULU
DUET4548A
Duet TRS™ 45 4.8MM ARTICULATING SULU
DUET6035
Duet TRS™ 60 3.5MM STRAIGHT SULU
DUET6035A
Duet TRS™ 60 3.5MM ARTICULATING SULU
DUET6048
Duet TRS™ 60 4.8MM STRAIGHT SULU
DUET6048A
Duet TRS™ 60 4.8MM ARTICULATING SULU

REQUIRED ACTIONS:

1 Immediately discontinue use of the device in thoracic surgery.
2 Immediately advise all surgeons / surgical personnel of this FSCA.
3 Complete form nr. 1 and return to the Covidien address listed. Your response is vital to monitor the effectiveness of this FSCA.
4 Product intended for thoracic use must be returned to Covidien by completing form nr. 2
5 If you are a Distributor please forward this communication to your customers immediately… (…read more: http://bit.ly/AdNLev)

Keywords:
DUET4535 Duet TRS™ 45 3.5MM STRAIGHT SULU, DUET4535A Duet TRS™ 45 3.5MM ARTICULATING SULU, DUET4548 Duet TRS™ 45 4.8MM STRAIGHT SULU, DUET4548A Duet TRS™ 45 4.8MM ARTICULATING SULU, DUET6035 Duet TRS™ 60 3.5MM STRAIGHT SULU. DUET6035A Duet TRS™ 60 3.5MM ARTICULATING SULU,
DUET6048 Duet TRS™ 60 4.8MM STRAIGHT SULU. DUET6048A Duet TRS™ 60 4.8MM ARTICULATING SULU, Raising money for a startup, serial entrepreneur, Outside The USA (OUS), Global Markets, Improve Execution, Optimize Innovation, Accelerate Globalization, Disruptive business model, Major emerging markets, Global growth goals, Collaborative partnership, Expanding insights into markets, Develop specific plans to accelerate global growth, Multinational, Increased pressure in utilization, Growth opportunity, acroMIS Implementation And Development, Sustainable growth, Slower growth of US markets, Delivering better economic value, Engaging primarily with the physician, Evaluated the merits of products, Clinical value, Demonstrate the economic value, Provider and payer levels, Deliver value, Prioritize investment, Biggest long-term opportunity, Meeting the needs, Solutions that deliver better economic value, Accelerated investments, Cost-effective solutions, Around the globe, Evolving Market, Reimbursement pressure, Declining procedure volume, Look for other solutions, Restructuring initiatives, Focus on emerging markets, Nascent technologies, Innovation and state-of-the-art medical technology, Progressive, Age-related disease, Standard of care, Unsuitable for open surgery, Meet the urgent need of patients, First mover advantage, OUS market, Enrollment in pilot study, Scheduled for completion, European market, Japanese market, Competitive landscape, Recent launches, Devices approved for procedures, Candidates in queue, Acquisition of technologies, Pivotal trial, Targeting a limited launch, CE Mark trial, Next-generation, Under development, Proper selection of patients, Choosing the right delivery method, Dealing with high risk complications, Overt risk, Address the high risk, Unfavorable reimbursement decision from the CMS, Adverse impact on technology, Considered as a first line therapy, Team work, Noninvasive, Necessity of the procedures to be performed in specialized centers, Training of the physicians and staff, Widespread rollout, Physicians’ learning curve, Attain the desired level of proficiency, Proper selection of patients, Economic potential, State-of-the-art procedure, Devices priced at hefty premium, Prevailing economic uncertainty, Adoption of austerity measures, Compete on price, Advantageous position, Less invasive treatment, Europe, Asia, Germany, Japan, Providing expertise. Early clinical evidence, Principle investigator, Key opinion leader KOL, First-in-man, Implementation, Commercialize medtech, Access to capital, Uncertain regulatory environment, Threats to the biomedical industry’s growth, biomedical company CEOs, CEO, FDA regulatory approval process, Biomedical industry, Biomedical cluster, Products in clinical development, Global leadership position, Availability of capital to fund future innovation, Regulatory framework based on consistency, Innovative technologies, Diverse funding sources, Government grants, Angel investors, Venture capital, Licensing agreements, Partnerships, Corporate partnerships as a source of financing, Corporate venture funding, Investment of corporate funds into external endeavors, Disease foundations, Non-governmental organizations NGO, Access to capital, Tax incentives for innovation, Coverage and reimbursement issues, Regulatory approval process in the world, Recreate the ecosystem, Leading biomedical region, Working collaboratively, Stakeholders, Maintain high standards of safety and effectiveness, Address patients’ need, Improving ability to attract investment and grow, Pharmaceuticals, Biotechnology, Medical devices, Diagnostics or medical equipment, NuVasive, nullify a patent, spinal fusion surgery, Medtronic, Infringement Verdict, infringed patents, implants capable of being inserted trans-laterally, between adjacent vertebrae, plate and screw system, stabilize vertebrae in the cervical spine, tissue retractor

Comments are closed.